SEC Form 4 · accession 0001493152-26-027467
PROVECTUS BIOPHARMACEUTICALS, INC. · PVCT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward Pershing
Officer — CEO · Director
Period of report
Jun 5, 2026
Accepted (ET)
Jun 5, 2026 · 2:58 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000315545
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8% Unsecured Convertible Promissory NoteF3,F4 | $2.862 | Jun 5, 2026 | M | — | D | Jun 5, 2025 | Jun 5, 2026 | Series D-1 Convertible Preferred Stock | 9,436 | — | D |
| Series D-1 Convertible Preferred StockF1,F2 | — | Jun 5, 2026 | M | 9,436 | A | Jun 5, 2026 | — | Common Stock | 94,360 | 2,857,285 | D |
Explanation of responses
- F1Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
- F2The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
- F3The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.
- F4On June 05, 2026, the 2025 Note was converted into 9,436 shares of Series D-1 Preferred Stock.